Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis
The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
In summary, available data demonstrate that IL-1 and TNF are the causative agents underlying the bone loss induced by estrogen deficiency. Indeed, these factors are produced in bone and the bone marrow, released in larger amounts from cells of estrogen-deficient subjects, and indispensable for reproducing the effects of estrogen deficiency in bone. These observations support the hypothesis that the bone sparing effect of estrogen is due to the ability of the hormone to block osteoclastogenesis, the activation of mature osteoclasts and, as recently demonstrated, the rate of apoptotic osteoclast death. Although IL-1 and TNF play a prominent causal role in these events, the bone-sparing effect of estrogen is mediated by numerous cytokines which, by simultaneously stimulating multiple target cells, induce effects that are not accounted for by any one single factor (Fig. 2). The ability of estrogen to regulate some, but not all, the cytokines involved in this process is not inconsistent with this hypothesis because cytokines have potent synergistic effects. Thus, a considerable increase in bone resorption may result from a relatively small increase in the concentration of only a few of the bone-resorbing factors present in the bone microenvironment. This concept is best illustrated by the study of Miyaura et al. demonstrating that the concentrations of either IL-1, IL-6, IL-6 receptor, or prostaglandins detected in the bone marrow of OVX mice are insufficient to account for the increased bone resorption caused by estrogen withdrawal. In contrast, the increase in bone resorption induced by OVX can be explained by the cumulative effects of these cytokines. Thus, a better understanding of the cooperative effects of cytokines and a recognition that the contribution of individual cytokines to postmenopausal bone loss varies with the passage of time after menopause are necessary to fully understand the mechanism of action of estrogen in bone. Although the relevance of individual bone-targeting cytokines in species specific, the development of transgenic mice with activatable or deactivatable promoters is likely to result in a further clarification of the integrated action of estrogen-regulated cytokines in human bone cells and lay the foundations for the use of cytokine inhibitors in the treatment of postmenopausal osteoporosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Estrogen acts via suppression of bone resorption [43–45]”
From The Effect of Tobacco Smoking on Bone Mass: An Overview of Pathophysiologic Mechanisms (2018) · cites this paper as [44]
In the citing paper
“In addition, estrogen inhibits osteoclast formation by reducing the levels of other osteoclastogenic cytokines such as IL-1, IL-6, IL-11, TNF-α, TNF-β, and M-CSF [160, 161].”
From Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells (2015) · cites this paper as [160]
Citations
Cites
Interleukin-1 and interleukin-1 antagonism
Dinarello, C. (1991) · Blood · doi:10.1182/blood.v77.8.1627.1627 · Cited by 2,304
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789
Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6
Jilka, R. L., Hangoc, G., Girasole, G., Passeri, G., Williams, D. C., Abrams, J. S., Boyce, B., Broxmeyer, H., & Manolagas, S. C. (1992) · Science · doi:10.1126/science.1621100 · Cited by 1,442
Bertolini, D. R., Nedwin, G. E., Bringman, T. S., Smith, D. D., & Mundy, G. R. (1986) · Nature · doi:10.1038/319516a0 · Cited by 1,434
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, D. G., Mundy, G. R., & Dr. Boyce, B. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101008 · Cited by 1,040
An interleukin 1 like factor stimulates bone resorption in vitro
Gowen, M., Wood, D. D., Ihrie, E. J., McGuire, M. K. B., & Russell, R. G. G. (1983) · Nature · doi:10.1038/306378a0 · Cited by 1,012
Modulation of Osteoclast Differentiation
SUDA, T., TAKAHASHI, N., & MARTIN, T. J. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-66 · Cited by 1,004 · cited 2×
“(22) These mice, which are cured by the administration of M-CSF,(3s) have an extra thymidine inserted within the coding region of the M-CSF gene, a mutation that generates a stop codon within the coding sequence,(3h) thereby resulting in the production of a defective M-CSF.(22) The formation of osteoclasts in bone mar…”
BackgroundSoluble interleukin-6 receptor triggers osteoclast formation by interleukin 6.
Tamura, T., Udagawa, N., Takahashi, N., Miyaura, C., Tanaka, S., Yamada, Y., Koishihara, Y., Ohsugi, Y., Kumaki, K., & Taga, T. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11924 · Cited by 825
TURNER, R. T., RIGGS, B. L., & SPELSBERG, T. C. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-3-275 · Cited by 754
Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion.
Poli, V., Balena, R., Fattori, E., Markatos, A., Yamamoto, M., Tanaka, H., Ciliberto, G., Rodan, G. A., & Costantini, F. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06368.x · Cited by 749
Research works printed but not linked: 11
- Srivastava, 1995, Estrogen down-regulates the expression of M-CSF mRNA in bone marrow stromal cells by stimulating the production of the transcription factor EGR-1, J Bone Miner Res, 10, S18
- Matayoshi, 1995, Generation of human osteoclasts from peripheral blood cd 34+ cells, J Bone Miner Res, 10
- Pacifici, 1990, TNFα and GM-CSF secretion from human blood monocytes: Effect of menopause and estrogen replacement, J Bone Miner Res, 5, 145
- Kimble, 1996, Estrogen inhibits IL-1 and TNF gene expression in transfected murine macrophagic cells, J Bone Miner Res, 11
- Kaneki, 1991, The effect of menopause on IL-1 and IL-6 release from peripheral blood monocytes, J Bone Miner Res, 6, 76
- Thompson, 1991, IL-lra: Properties and uses of an interleukin-1 receptor antagonist, Agents Actions, 41
- Girasole, 1995, Increased serum soluble interleukin-6 receptor levels are induced by ovariectomy, prevented by estrogen replacement, and reversed by alendronate administration, J Bone Miner Res, 10, A86
- McKane, 1993, Effect of age and menopause on serum interleukin-1β and intereleukin-6- levels in women, J Bone Miner Res, 8, 162A
- Kimble, 1994, Long-term treatment with IL-1 receptor antagonist (IL-lra) blocks bone loss in ovariectomized rats, J Bone Miner Res, 9, B380
- Kimble, 1995, Inhibition of IL-6 activity is genetically normal mice does not prevent ovariectomy-induced bone loss, J Bone Miner Res, 10, s160
- Ammann, 1995, Transgenic mice expressing high levels of soluble tumor necrosis factor receptor-1 fusion protein are protected from bone loss caused by estrogen deficiency, J Bone Miner Res, 10
Cited by
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
“Some systemic and local factors that regulate development and interplay between osteoclasts and osteoblasts have been identified (Mundy 1993a,b; Erlebacher and Derynck 1996; Manolagas and Jilka 1995; Hughes et al. 1996; Pacifici 1996).”
BackgroundBiology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells
Florencio-Silva, R., Sasso, G. R. D. S., Sasso-Cerri, E., Simões, M. J., & Cerri, P. S. (2015) · BioMed Research International · doi:10.1155/2015/421746 · Cited by 2,044
“High mobility group box protein 1 (HMGB1) [198–200] and M-CSF [201] have also been suggested to be produced by osteocytes that stimulate osteoclast recruitment during bone remodeling [72, 73].”
BackgroundInfluentialSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
“row (31, 73), and precursors of both cell types in bone marrow”
BackgroundInfluentialSambrook, P., & Cooper, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68891-0 · Cited by 1,165
Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Boyle, W. J., & Riggs, B. L. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.2 · Cited by 1,173
Bode, C., Zhao, G., Steinhagen, F., Kinjo, T., & Klinman, D. M. (2011) · Expert Review of Vaccines · doi:10.1586/erv.10.174 · Cited by 891
Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction.
Tatsumi, S., Ishii, K., Amizuka, N., Li, M., Kobayashi, T., Kohno, K., Ito, M., Takeshita, S., & Ikeda, K. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.001 · Cited by 848
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825
“The mechanism of estrogen suppression of osteoclast formation and function is complex and involves multiple cytokine mediators (1, 3, 4).”
BackgroundInfluentialSerum IL‐6 Level and the Development of Disability in Older Persons
Ferrucci, L., Harris, T. B., Guralnik, J. M., Tracy, R. P., Corti, M., Cohen, H. J., Penninx, B., Pahor, M., Wallace, R., & Havlik, R. J. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb01583.x · Cited by 809
Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794
Prevention and treatment of postmenopausal osteoporosis
Tella, S. H., & Gallagher, J. C. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.09.008 · Cited by 786
“Teriparatide—Teriparatide (rDNA origin) injection contains recombinant human parathyroid hormone hPTH(1-34)] that has an identical sequence to the 34 N-terminal amino acids (the biologically active region) of the 84-amino acid human parathyroid hormone.”
BackgroundInfluentialKenkre, J., & Bassett, J. (2018) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563218759371 · Cited by 693
“Oestrogen deficiency results in an increase in IL-1, IL-6 and TNFa, leading to an increased RANKL expression and increased osteoclastogenesis and bone resorption.(139)”
BackgroundInteraction between bone and immune cells: Implications for postmenopausal osteoporosis
Fischer, V., & Haffner-Luntzer, M. (2022) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2021.05.014 · Cited by 759
Falahati-Nini, A., Riggs, B. L., Atkinson, E. J., O’Fallon, W. M., Eastell, R., & Khosla, S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10942 · Cited by 757
Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α
Cenci, S., Weitzmann, M. N., Roggia, C., Namba, N., Novack, D., Woodring, J., & Pacifici, R. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11066 · Cited by 705
“Discussion Estrogen prevents bone loss through multiple effects on bone marrow and bone cells, which result in decreased osteoclast formation (4, 5), increased osteoclast apoptosis (25), and decreased capacity of mature osteoclasts to resorb bone (26).”
BackgroundSelf-citationHofbauer, L. C., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., Riggs, B. L., & Khosla, S. (1999) · Bone · doi:10.1016/s8756-3282(99)00162-3 · Cited by 631
Inhibition of Osteoblast Differentiation by Tumor Necrosis Factor-α*
Gilbert, L., He, X., Farmer, P., Boden, S., Kozlowski, M., Rubin, J., & Nanes, M. S. (2000) · Endocrinology · doi:10.1210/endo.141.11.7739 · Cited by 555
Kon, T., Cho, T.-J., Aizawa, T., Yamazaki, M., Nooh, N., Graves, D., Gerstenfeld, L. C., & Einhorn, T. A. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.6.1004 · Cited by 552
“(19,20) Levels of TNF-a production and IL-1 expression in monocytes have been shown to be elevated in surgically produced or naturally occurring menopausal states, and a number of studies have shown that TNF-a can induce osteoclast formation in vitro.”
BackgroundMin, H., Morony, S., Sarosi, I., Dunstan, C. R., Capparelli, C., Scully, S., Van, G., Kaufman, S., Kostenuik, P. J., Lacey, D. L., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.4.463 · Cited by 550
“In contrast, OPG-deficient mice (OPG 2/2 ) exhibited an overall decrease in total bone density and a high incidence of fractures (4, 5), reminiscent of postmenopausal osteoporosis in human populations (6).”
BackgroundShevde, N. K., Bendixen, A. C., Dienger, K. M., & Pike, J. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130200197 · Cited by 502
McComsey, G. A., Kitch, D., Daar, E. S., Tierney, C., Jahed, N. C., Tebas, P., Myers, L., Melbourne, K., Ha, B., & Sax, P. E. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir188 · Cited by 495
“Furthermore, cytokines, such as IL-6 and TNF-a, may stimulate osteoclast activity [33–35].”
BackgroundColbert, L. H., Visser, M., Simonsick, E. M., Tracy, R. P., Newman, A. B., Kritchevsky, S. B., Pahor, M., Taaffe, D. R., Brach, J., Rubin, S., et al. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52307.x · Cited by 464
The mechanisms of estrogen regulation of bone resorption
Riggs, B. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11468 · Cited by 446
“1204 The Journal of Clinical Investigation | November 2000 | Volume 106 | Number 10 stimulation of RANKL production (3, 5), since TNF-α fails to induce OC formation in BMMs from OVX mice lacking the p55 TNF-α receptor (TNF-R1).”
BackgroundInfluentialTumor necrosis factor-α: molecular and cellular mechanisms in skeletal pathology
Nanes, M. S. (2003) · Gene · doi:10.1016/s0378-1119(03)00841-2 · Cited by 440
Osteoporosis and periodontal diseases – An update on their association and mechanistic links
Yu, B., & Wang, C. (2022) · Periodontology 2000 · doi:10.1111/prd.12422 · Cited by 407
Taaffe, D. R., Harris, T. B., Ferrucci, L., Rowe, J., & Seeman, T. E. (2000) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/55.12.m709 · Cited by 438
Classical and Paradoxical Effects of TNF-α on Bone Homeostasis
Osta, B., Benedetti, G., & Miossec, P. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00048 · Cited by 387
Nordin, B. E. C. (1997) · Nutrition · doi:10.1016/s0899-9007(97)83011-0 · Cited by 367
The role of the immune system in the pathophysiology of osteoporosis
Clowes, J. A., Riggs, B. L., & Khosla, S. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00334.x · Cited by 359
“IL-6 stimulates osteoclastogenesis in vitro (15, 34, 88) and in vivo ovariectomy results in an increase in IL-6 production, bone loss, and osteoclastogenesis.”
BackgroundInfluentialYano, K., Tsuda, E., Washida, N., Kobayashi, F., Goto, M., Harada, A., Ikeda, K., Higashio, K., & Yamada, Y. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.4.518 · Cited by 363
“kines that regulate osteoclastic bone resorption, including tumor necrosis factor (TNF),((12)) interleukin-1,((12)) interleukin-6,((13)) and transforming growth factor-b,((14)) are thought”
BackgroundSrivastava, S., Toraldo, G., Weitzmann, M. N., Cenci, S., Ross, F. P., & Pacifici, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010764200 · Cited by 358
Self-citationVanacker, J.-M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.15.4270 · Cited by 340
An, J., Tzagarakis-Foster, C., Scharschmidt, T. C., Lomri, N., & Leitman, D. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100953200 · Cited by 323
Yamada, Y., Miyauchi, A., Goto, J., Takagi, Y., Okuizumi, H., Kanematsu, M., Hase, M., Takai, H., Harada, A., & Ikeda, K. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.10.1569 · Cited by 321
“In addition, TGF-b has been implicated as a mediator of the skeletal effects of estrogen.((30)) The production of TGF-b1 by human osteoblastic cells is stimulated by 17b-estradiol,((31)) and the TGF-b1 contributes to the estrogen-induced apoptosis of osteoclasts, which results in reduced bone resorption.”
BackgroundMenopause and aging: Changes in the immune system—A review
Gameiro, C. M., Romão, F., & Castelo-Branco, C. (2010) · Maturitas · doi:10.1016/j.maturitas.2010.08.003 · Cited by 303
Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification
Doherty, T. M., Fitzpatrick, L. A., Inoue, D., Qiao, J.-H., Fishbein, M. C., Detrano, R. C., Shah, P. K., & Rajavashisth, T. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0015 · Cited by 299
Takai, H., Kanematsu, M., Yano, K., Tsuda, E., Higashio, K., Ikeda, K., Watanabe, K., & Yamada, Y. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.42.27091 · Cited by 299
Dietary n-3 Fatty Acids Decrease Osteoclastogenesis and Loss of Bone Mass in Ovariectomized Mice
Sun, D., Krishnan, A., Zaman, K., Lawrence, R., Bhattacharya, A., & Fernandes, G. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.7.1206 · Cited by 291
“It is well established that osteoporosis associated with a decline in estrogen production in postmenopausal women results in increased production of several osteoclastogenic cytokines such as IL-1, IL-6, and TNF- .((44,56)) These cytokines induce the expression of COX-II in osteoblastic and stromal cells, resulting in…”
BackgroundSkeletal and Hormonal Effects of Magnesium Deficiency
Rude, R. K., Singer, F. R., & Gruber, H. E. (2009) · Journal of the American College of Nutrition · doi:10.1080/07315724.2009.10719764 · Cited by 285
“Increased production of these cytokines has been implicated in the development of sex steroid deficiency or postmenopausal osteoporosis [78,79].”
BackgroundThe effects of smoking on bone metabolism
Yoon, V., Maalouf, N. M., & Sakhaee, K. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1940-y · Cited by 268
Total oxidative/anti-oxidative status and relation to bone mineral density in osteoporosis
Altindag, O., Erel, O., Soran, N., Celik, H., & Selek, S. (2008) · Rheumatology International · doi:10.1007/s00296-007-0452-0 · Cited by 260
Yang, N., Wang, G., Hu, C., Shi, Y., Liao, L., Shi, S., Cai, Y., Cheng, S., Wang, X., Liu, Y., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1798 · Cited by 255
“Previous studies have shown that the levels of TNF-a, IL-1b, and IFN-g were increased due to estrogen deficiency in osteoporosis.((1,5)) To determine whether inflammatory cytokines affect the expression of miR-21 during MSC osteoblast differentiation, N-hMSCs were cultured in osteoblast differentiation medium in the p…”
ResultScheidt-Nave, C. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.5.2032 · Cited by 255
“1 (9) Health status since baseline, n (%) Immobilization .”
BackgroundSrivastava, S., Weitzmann, M. N., Cenci, S., Ross, F. P., Adler, S., & Pacifici, R. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7094 · Cited by 255
“Inhibition of TNF production is one of the mechanisms by which E2 prevents osteoclast formation and bone loss (67).”
BackgroundSelf-citationProinflammatory cytokines and osteoporosis
McLean, R. R. (2009) · Current Osteoporosis Reports · doi:10.1007/s11914-009-0023-2 · Cited by 248
Miller, G. D., Nicklas, B. J., Davis, C., Loeser, R. F., Lenchik, L., & Messier, S. P. (2006) · Obesity · doi:10.1038/oby.2006.139 · Cited by 248
Cross-talk between nuclear receptors and nuclear factor κB
De Bosscher, K., Vanden Berghe, W., & Haegeman, G. (2006) · Oncogene · doi:10.1038/sj.onc.1209935 · Cited by 247
Vega, D., Maalouf, N. M., & Sakhaee, K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0646 · Cited by 246
Connection Between B Lymphocyte and Osteoclast Differentiation Pathways
Manabe, N., Kawaguchi, H., Chikuda, H., Miyaura, C., Inada, M., Nagai, R., Nabeshima, Y.-I., Nakamura, K., Sinclair, A. M., Scheuermann, R. H., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.5.2625 · Cited by 240
“Estrogen withdrawal causes a marked increase in the number of both B220 cells (containing pro-B cells) and osteoclasts, which leads to bone loss in humans (postmenopausal osteoporosis), and mice (osteopenia caused by ovariectomy) (1, 22, 23).”
BackgroundMaruyama, Z., Yoshida, C. A., Furuichi, T., Amizuka, N., Ito, M., Fukuyama, R., Miyazaki, T., Kitaura, H., Nakamura, K., Fujita, T., et al. (2007) · Developmental Dynamics · doi:10.1002/dvdy.21187 · Cited by 232
“Estrogen inhibits osteoclastogenesis, and the estrogen receptor interacts with Runx2, enhancing transcriptional activation by Runx2 (Manolagas and Jilka, 1995; Pacifici, 1996; McCarthy et al., 2003).”
BackgroundPathogenesis of Age-Related Bone Loss in Humans
Khosla, S. (2013) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/gls163 · Cited by 222
“In addition, a number of these cytokines act upstream of RANKL in expanding the pool of preosteoclastic cells (25).”
BackgroundIL-1 plays an important role in the bone metabolism under physiological conditions
Lee, Y.-M., Fujikado, N., Manaka, H., Yasuda, H., & Iwakura, Y. (2010) · International Immunology · doi:10.1093/intimm/dxq431 · Cited by 226
Osteoporosis and Periodontitis
Wang, C.-W., & McCauley, L. K. (2016) · Current Osteoporosis Reports · doi:10.1007/s11914-016-0330-3 · Cited by 204
Interaction between osteoblast and osteoclast: impact in bone disease.
Phan, T. C. A., Xu, J., & Zheng, M. (2004) · PubMed · doi:10.14670/hh-19.1325 · Cited by 206
The Effect of Tobacco Smoking on Bone Mass: An Overview of Pathophysiologic Mechanisms
Al-Bashaireh, A. M., Haddad, L. G., Weaver, M., Chengguo, X., Kelly, D. L., & Yoon, S. (2018) · Journal of Osteoporosis · doi:10.1155/2018/1206235 · Cited by 209
Editorial: Cytokines, Estrogen, and Postmenopausal Osteoporosis—The Second Decade
Pacifici, R. (1998) · Endocrinology · doi:10.1210/endo.139.6.6087 · Cited by 194
“increases blood, bone marrow, and monocytic levels of IL-1, IL-6, TNF, and the related factors IL-1ra and IL-6R (1, 2).”
BackgroundInfluentialSelf-citationHögström, M., Nordström, P., & Nordström, A. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/85.3.803 · Cited by 201
In vitro Models of Bone Remodelling and Associated Disorders
Owen, R., & Reilly, G. C. (2018) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2018.00134 · Cited by 182
“For example, the discovery of interleukin-6 and M-CSF, as well as the RANKL/RANK/OPG axis that mediates osteoclast formation and function (McSheehy and Chambers, 1986; Ishimi et al., 1990; Greenfield et al., 1992; Jimi et al., 1996; Pacifici, 1996; Feng and McDonald, 2011).”
BackgroundInfluence of Estrogen and Osteopenia/Osteoporosis on Clinical Periodontitis in Postmenopausal Women
Reinhardt, R. A., Payne, J. B., Maze, C. A., Patil, K. D., Gallagher, S. J., & Mattson, J. S. (1999) · Journal of Periodontology · doi:10.1902/jop.1999.70.8.823 · Cited by 195
Tumor Necrosis Factor Receptors Types 1 and 2 Differentially Regulate Osteoclastogenesis
Abu-Amer, Y., Erdmann, J., Alexopoulou, L., Kollias, G., Ross, F. P., & Teitelbaum, S. L. (2000) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)61511-5 · Cited by 195
Saika, M., Inoue, D., Kido, S., & Matsumoto, T. (2001) · Endocrinology · doi:10.1210/endo.142.6.8220 · Cited by 194
“Previous studies have identified several candidate mediators of the increased bone resorption (5, 6).”
BackgroundWang, Y., Li, L., Moore, B. T., Peng, X.-H., Fang, X., Lappe, J. M., Recker, R. R., & Xiao, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034641 · Cited by 188
“Circulating monocytes are important cells that participate in osteoclatogenesis by acting as osteoclast precursors [19–22] and secreting osteoclastogenesis-related factors, such as IL-1 (interleukin-1), IL-6 and TNF-a (tumor necrosis factor-alpha) [23–25].”
BackgroundThe role of T lymphocytes in bone metabolism
Weitzmann, M. N., & Pacifici, R. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00324.x · Cited by 192
“The osteoclastogenic response to all three cytokines in vitro was based on sound data (82, 83).”
BackgroundSelf-citationAukrust, P., Haug, C. J., Ueland, T., Lien, E., Müller, F., Espevik, T., Bollerslev, J., & Frøland, S. S. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.1.5417 · Cited by 182
Impact of Tobacco Use on Periodontal Status
Johnson, G. K., & Slach, N. A. (2001) · Journal of Dental Education · doi:10.1002/j.0022-0337.2001.65.4.tb03401.x · Cited by 191
Osteoclastogenesis, Bone Resorption, and Osteoclast-Based Therapeutics
Zaidi, M., Blair, H. C., Moonga, B. S., Abe, E., & Huang, C. L.-H. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.4.599 · Cited by 180
“Second, deletion of the genes of most cytokines or their receptors, including IL-6 and TNF , do not produce pronounced osteoclastic defects, confirming that the respective cytokines are not obligatory for osteoclast formation.((44)) Nonetheless, bone phenotypes often become apparent in the presence of physiological st…”
BackgroundHofbauer, L. C., & Heufelder, A. E. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6702 · Cited by 169
Nagy, V., & Penninger, J. M. (2015) · Gerontology · doi:10.1159/000371845 · Cited by 171
The pathogenesis, diagnosis, investigation and management of osteoporosis
Sandhu, S. K., & Hampson, G. (2011) · Journal of Clinical Pathology · doi:10.1136/jcp.2010.077842 · Cited by 172
Distinct Roles of Unliganded and Liganded Estrogen Receptors in Transcriptional Repression
Cvoro, A., Tzagarakis-Foster, C., Tatomer, D., Paruthiyil, S., Fox, M. S., & Leitman, D. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.014 · Cited by 170
“, 2002) that contribute to inflammatory conditions, such as osteoporosis (Ammann et al., 1997; Pacifici, 1996), cardiovascular disease (Pai et al.”
BackgroundMethodInfluentialKanematsu, M., Sato, T., Takai, H., Watanabe, K., Ikeda, K., & Yamada, Y. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.7.1321 · Cited by 174
“The cells were washed and resuspended in PBS(2) containing 0.1% (wt/vol) bovine serum albumin, and then they were incubated for 30 minutes with FITC-anti–IgG (5 mg/ml).”
BackgroundMethodInfluentialDou, C., Ding, N., Zhao, C., Hou, T., Kang, F., Cao, Z., Liu, C., Bai, Y., Dai, Q., Ma, Q., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3364 · Cited by 166
“bone protection, it is clear that estrogen can directly induce apoptosis of the bone-resorbing osteoclasts((17)); however, the pool size of non–bone-resorbing preosteoclast is also downregulated by estrogen,((18,19)) but the detailed mechanism remains unknown.”
BackgroundExercise for osteoporosis: A literature review of pathology and mechanism
Zhang, L., Zheng, Y.-L., Wang, R., Wang, X., & Zhang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1005665 · Cited by 199
“By increasing the signal of Ras/Rac1/Erk and PI3 kinase/mTOR/S6K, cytokines such as macrophage colonystimulating factor (M-CSF), RANKL, tumor necrosis factor (TNF), and VEGF can slow down apoptosis and improve the survival rate of OCs, which is linked to the rise in bone resorption (12).”
BackgroundRaloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice
Erlandsson, M., Jonsson, C., Lindberg, M., Ohlsson, C., & Carlsten, H. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1750319 · Cited by 165
“The postmenopausal osteoporosis induced by estrogen deficiency is primarily caused by an increased osteoclast formation (Pacifici 1996).”
BackgroundInfluentialBendixen, A. C., Shevde, N. K., Dienger, K. M., Willson, T. M., Funk, C. D., & Pike, J. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041493198 · Cited by 161
Ammann, P., Bourrin, S., Bonjour, J.-P., Meyer, J.-M., & Rizzoli, R. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.4.683 · Cited by 157
Regulation of adult bone turnover by sex steroids
Frenkel, B., Hong, A., Baniwal, S. K., Coetzee, G. A., Ohlsson, C., Khalid, O. S., & Gabet, Y. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22159 · Cited by 165
“Alternatively, ERa may attenuate expression of genes in osteoclasts in a non-classical fashion, for example by inhibiting NFkB (Ray et al., 1994), or by antagonizing JNK activity, thus limiting RANKL-mediated activation of AP-1 target genes (Srivastava et al., 2001).”
BackgroundSex hormone levels correlate with the activity of cytokine‐secreting cells in vivo
Verthelyi, D., & Klinman, D. M. (2000) · Immunology · doi:10.1046/j.1365-2567.2000.00047.x · Cited by 148
“Previous studies investigating the interaction between the neuroendocrine and immune systems generally focused on subjects with autoimmune disease(5,6,13) or undergoing profound changes in oestrogen levels (due to oophorectomy, discontinuation of oestrogen replacement therapy or menopause).(24,25) Few studies addresse…”
BackgroundNAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome
Rosato, V., Masarone, M., Dallio, M., Federico, A., Aglitti, A., & Persico, M. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16183415 · Cited by 166
“As is well known, estrogen plays a protective role in the development of osteoporosis, indirectly inhibiting osteoclast activity through the down-regulation of pro-inflammatory cytokines (IL-1, IL-6, TNF-α, M-CSF) and the up-regulation of TGF-ß, an inhibitor of bone resorption [122].”
BackgroundLow lumbar spine bone mineral density in both male and female endurance runners
Hind, K., Truscott, J. G., & Evans, J. A. (2006) · Bone · doi:10.1016/j.bone.2006.03.012 · Cited by 105
Takeuchi, Y., Watanabe, S., Ishii, G., Takeda, S., Nakayama, K., Fukumoto, S., Kaneta, Y., Inoue, D., Matsumoto, T., Harigaya, K., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207804200 · Cited by 143
Human Cell Culture: Volume VI: Embryonic Stem Cells
Masters, J. R., Thomson, J. A., & Palsson, B. Ø. (2007) · Human cell culture · doi:10.1007/978-1-4020-5983-4 · Cited by 144
Can Systemic Diseases Co-induce ( Not Just Exacerbate) Periodontitis? A Hypothetical “Two-hit” Model
Golub, L. M., Payne, J. B., Reinhardt, R., & Nieman, G. F. (2006) · Journal of Dental Research · doi:10.1177/154405910608500201 · Cited by 165
“Estrogen deficiency in post-menopausal women is the major cause of osteoporosis in humans (Pacifici, 1996).”
BackgroundSelective Estrogen Receptor-β Agonists Repress Transcription of Proinflammatory Genes
Cvoro, A., Tatomer, D., Tee, M.-K., Zogovic, T., Harris, H. A., & Leitman, D. C. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.630 · Cited by 138
“Most of these genes were known proinflammatory genes, such as TNF- , IL-6, and IL-8 (4, 6, 44, 45).”
BackgroundIn Vitro Secretion of Cytokines by Human Bone Marrow: Effects of Age and Estrogen Status1
Cheleuitte, D., Mizuno, S., & Glowacki, J. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.6.4848 · Cited by 127
Sunyer, T., Lewis, J., Collin-Osdoby, P., & Osdoby, P. (1999) · Journal of Clinical Investigation · doi:10.1172/jci4682 · Cited by 139
Androgen effects on bone metabolism: recent progress and controversies
Hofbauer, L., & Khosla, S. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1400271 · Cited by 136
Regulatory roles and molecular signaling of TNF family members in osteoclasts
Feng, X. (2005) · Gene · doi:10.1016/j.gene.2005.01.014 · Cited by 152
The pathophysiology of otosclerosis: Review of current research
Rudić, M., Keogh, I. J., Wagner, R. A., Wilkinson, E. P., Kiros, N., Ferrary, É., Sterkers, O., Grayeli, A. B., Žarković, K., & Žarković, N. (2015) · Hearing Research · doi:10.1016/j.heares.2015.07.014 · Cited by 130
Watkins, B. A., Li, Y., & Seifert, M. F. (2005) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2005.05.012 · Cited by 142
“The elevation of these cytokines and PGE2 during menopause aggravates the symptoms of estrogen deficiency in the bone [6].”
BackgroundMorabito, N., Gaudio, A., Lasco, A., Atteritano, M., Pizzoleo, M. A., Cincotta, M., La Rosa, M., Guarino, R., Meo, A., & Frisina, N. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040113 · Cited by 127
Madeddu, G., Spanu, A., Solinas, P., Calia, G. M., Lovigu, C., Chessa, F., Mannazzu, M., Falchi, A., Mura, M. S., & Madeddu, G. (2004) · PubMed · Cited by 127
Changes in serum cytokine concentrations during the menopausal transition
Yasui, T., Maegawa, M., Tomita, J., Miyatani, Y., Yamada, M., Uemura, H., Matsuzaki, T., Kuwahara, A., Kamada, M., Tsuchiya, N., et al. (2006) · Maturitas · doi:10.1016/j.maturitas.2006.11.002 · Cited by 136
“[4] Pacifici R.”
BackgroundAromatase Inhibitors and Bone Health in Women With Breast Cancer
Chien, A. J., & Goss, P. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.5382 · Cited by 133
Physiologic regulators of bone turnover in young women with anorexia nervosa
Gordon, C. M., Goodman, E., Emans, S. J., Grace, E., Becker, K. A., Rosen, C. J., Gundberg, C. M., & LeBoff, M. S. (2002) · The Journal of Pediatrics · doi:10.1067/mpd.2002.125003 · Cited by 129
Molecular-Based Treatment Strategies for Osteoporosis: A Literature Review
Ukon, Y., Makino, T., Kodama, J., Tsukazaki, H., Tateiwa, D., Yoshikawa, H., & Kaito, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102557 · Cited by 128
“Therefore, contrary to the original hypothesis, the main contribution to bone loss in the setting of estrogen deficiency seems to be an increase in bone resorption, not impaired bone formation [90].”
BackgroundTurgeman, G., Zilberman, Y., Zhou, S., Kelly, P., Moutsatsos, I. K., Kharode, Y. P., Borella, L. E., Bex, F. J., Komm, B. S., Bodine, P. V. N., et al. (2002) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10231 · Cited by 123
“This type of bone loss is caused principally by an increase in cytokines, such as IL-1, IL-6, TNF-a, M-CSF, and GM-CSF, which promote osteoclastogenesis and subsequent bone resorption [Pacifici, 1996, 1998; Jilka, 1998].”
BackgroundCheng, S., Sipilä, S., Taaffe, D. R., Puolakka, J. O., & Suominen, H. (2002) · Bone · doi:10.1016/s8756-3282(02)00794-9 · Cited by 135
Allali, F., Bréban, M., Porcher, R., Maillefert, J.-F., Dougados, M., & Roux, C. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.4.347 · Cited by 133
Rutkowski, P., Kamińska, J., Kowalska, M., Ruka, W., & Steffen, J. (2003) · Journal of Surgical Oncology · doi:10.1002/jso.10305 · Cited by 117
Metadata
- Authors
- Pacifici, R.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Pacifici, Roberto
- ORCID
- Pacifici, Roberto
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1996-08-01
- Volume
- 11
- Issue
- 8
- Pages
- 1043-1051
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2110993073
- Cited by
- 741
- References
- 90
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 15 · 2023: 20 · 2022: 20 · 2021: 24 · 2020: 20 · 2019: 26 · 2018: 30 · 2017: 15 · 2016: 19 · 2015: 31 · 2014: 29 · 2013: 22 · 2012: 28
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ag013534-04)
- National Institute on Aging (AG 13534)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR041412, AR41412)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- postmenopausal osteoporosis, estrogen deficiency, cytokines, interleukin-1, TNF-α, bone resorption, osteoclastogenesis, osteoclast apoptosis, bone marrow, cytokine synergy, estrogen withdrawal, cytokine inhibitors
- MeSH terms
- Animals, Bone and Bones, Bone Resorption, Estrogens, Female, Humans, Menopause, Osteoporosis, Postmenopausal, Estrogen Replacement Therapy, Cytokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.